News articles about Baxter International (NYSE:BAX) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Baxter International earned a news impact score of 0.16 on Accern’s scale. Accern also gave media stories about the medical instruments supplier an impact score of 46.2796945451641 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news stories that may have effected Accern’s rankings:
- Technical Facts for Investment in Baxter International Inc. (BAX) – Wall Street Morning (wallstreetmorning.com)
- Optimistic Trending Companies: BorgWarner Inc. (BWA), Baxter International Inc. (BAX) – Market Movers (financialqz.com)
- Baxter (BAX) Launches Arisure Closed System Transfer Device – Nasdaq (nasdaq.com)
- Hospitals find other ways to deliver medicine amid IV bag shortage – WHAS 11.com (whas11.com)
- IV bag shortage forces hospitals to preserve resources (upi.com)
Baxter International (NYSE:BAX) traded down $0.67 during trading hours on Tuesday, hitting $67.67. 4,225,500 shares of the stock traded hands, compared to its average volume of 3,227,280. Baxter International has a one year low of $45.47 and a one year high of $69.65. The company has a debt-to-equity ratio of 0.37, a quick ratio of 2.22 and a current ratio of 2.80. The company has a market cap of $36,920.00, a P/E ratio of 36.58, a price-to-earnings-growth ratio of 2.05 and a beta of 0.69.
The firm also recently declared a quarterly dividend, which was paid on Tuesday, January 2nd. Investors of record on Friday, December 1st were paid a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.95%. The ex-dividend date was Thursday, November 30th. Baxter International’s dividend payout ratio (DPR) is 34.59%.
BAX has been the topic of a number of research analyst reports. Zacks Investment Research upgraded shares of Baxter International from a “hold” rating to a “buy” rating and set a $72.00 price target on the stock in a research report on Tuesday, October 24th. Royal Bank of Canada restated a “hold” rating and issued a $66.00 price target on shares of Baxter International in a research report on Wednesday, November 22nd. Bank of America restated a “hold” rating on shares of Baxter International in a research report on Wednesday, November 22nd. Morgan Stanley raised their price objective on shares of Baxter International from $59.00 to $62.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 26th. Finally, Cowen reaffirmed a “neutral” rating on shares of Baxter International in a research note on Friday, October 13th. Seven equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $68.64.
In other news, Director Third Point Llc sold 5,000,000 shares of the stock in a transaction on Monday, November 6th. The shares were sold at an average price of $64.23, for a total transaction of $321,150,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Jeanne K. Mason sold 33,350 shares of the stock in a transaction on Monday, December 4th. The stock was sold at an average price of $65.25, for a total transaction of $2,176,087.50. Following the transaction, the senior vice president now owns 124,609 shares of the company’s stock, valued at approximately $8,130,737.25. The disclosure for this sale can be found here. Insiders sold 5,061,991 shares of company stock valued at $325,245,035 in the last ninety days. Insiders own 0.05% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Baxter International (NYSE:BAX) Stock Price” was originally published by BBNS and is the sole property of of BBNS. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://baseballnewssource.com/markets/baxter-international-bax-earns-coverage-optimism-score-of-0-16/1821305.html.
Baxter International Company Profile
Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.